Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults

H. Yu (Shanghai, China), Y. Liu (Shanghai, China), K. Shen (Shanghai, China), P. Assam (Shanghai, China), M. Gillen (Gaithersburg, United States of America), P. Dorinsky (Durham, United States of America)

Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Session: Pulmonary drug delivery: inhaler use, devices and technologies
Session type: Thematic Poster
Number: 1013
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Yu (Shanghai, China), Y. Liu (Shanghai, China), K. Shen (Shanghai, China), P. Assam (Shanghai, China), M. Gillen (Gaithersburg, United States of America), P. Dorinsky (Durham, United States of America). Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults. 1013

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: